Bryan Ball Sells 92,460 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Key Points

• Bryan Ball sold 92,460 shares of Whitehawk Therapeutics on April 14 at an average price of $3.64 (≈$336,554), reducing his stake by 18.89% to 397,106 shares; the sale was disclosed as covering tax withholding on vested equity awards.
• WHWK shares recently traded around $3.90 with volume above average, a 1‑year range of $1.39–$4.48, a market cap of about $184 million, and 50‑/200‑day moving averages of $3.40 and $2.76 respectively.
• Analyst views are mixed — consensus rating is a Hold with a $6.50 price target (two Buys, one Hold, one Sell), while institutional ownership is ~52% and several funds opened new positions recently.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) insider Bryan Ball sold 92,460 shares of the stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $3.64, for a total value of $336,554.40. Following the sale, the insider directly owned 397,106 shares in the company, valued at $1,445,465.84. This trade represents a 18.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Monday, April 13th, Bryan Ball sold 26,389 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.46, for a total value of $91,305.94.
• On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.43, for a total value of $22,624.28.
• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total value of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total value of $6,070.54.

Whitehawk Therapeutics Stock Performance

Shares of Whitehawk Therapeutics stock traded down $0.10 on Wednesday, hitting $3.90. The company's stock had a trading volume of 316,487 shares, compared to its average volume of 187,321. Whitehawk Therapeutics, Inc. has a 1 year low of $1.39 and a 1 year high of $4.48. The firm has a fifty day moving average price of $3.40 and a 200-day moving average price of $2.76. The company has a market capitalization of $184.08 million, a price-to-earnings ratio of 8.30 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.21.

Analyst Ratings Changes

Several research firms have commented on WHWK. Weiss Ratings reiterated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Wall Street Zen lowered Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Oppenheimer began coverage on Whitehawk Therapeutics in a research note on Thursday, February 5th. They set an "outperform" rating and a $6.00 price objective for the company. Finally, JonesTrading began coverage on Whitehawk Therapeutics in a research note on Monday, December 22nd. They set a "buy" rating and a $7.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $6.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. KVP Capital Advisors LP acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $5,242,000. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $28,000. Eversept Partners LP acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $630,000. ADAR1 Capital Management LLC acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $188,000. Finally, Marshall Wace LLP acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $164,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.